(Q37377021)

20 August 2017

1 reference

title

BRCA1 and implications for response to chemotherapy in ovarian cancer (English)

1 reference

20 August 2017

1 reference

1 reference

Jennifer E Quinn

1

1 reference

20 August 2017

Judith E Carser

2

1 reference

20 August 2017

Colin R James

3

1 reference

20 August 2017

Richard D Kennedy

4

1 reference

20 August 2017

D Paul Harkin

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

24 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

113

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

134-142

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA: the breast, ovarian, and other cancer genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

7 January 2021

TP53 and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Critical evaluation of p53 as a prognostic marker in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Mismatch repair and treatment resistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Characterization of BRCA1 and BRCA2 mutations in a large United States sample

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Increased frequency ofTP53 mutations inBRCA1 andBRCA2 ovarian tumours

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Pathology of ovarian cancers in BRCA1 and BRCA2 carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Reduction of BRCA1 expression in sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Frequency of BRCA1 dysfunction in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Gene-Expression Profiles in Hereditary Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1, a potential predictive biomarker in the treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Role played by BRCA1 in transcriptional regulation in response to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

The role of BRCA1 in transcriptional regulation and cell cycle control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Platinum resistance: the role of DNA repair pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Molecular mechanism of nucleotide excision repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 required for transcription-coupled repair of oxidative DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

The carboxyl-terminal of BRCA1 is required for subnuclear assembly of RAD51 after treatment with cisplatin but not ionizing radiation in human breast and ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

A mouse model for the molecular characterization of brca1-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

The Fanconi Anemia/BRCA pathway: new faces in the crowd

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Roles of BRCA1 in DNA damage repair: a link between development and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 Facilitates Stress-induced Apoptosis in Breast and Ovarian Cancer Cell Lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Improved survival in women with BRCA-associated ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Prognostic impact ofBRCA1 pathogenic andBRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Is It Time to Stratify for BRCA Mutation Status in Therapeutic Trials in Ovarian Cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.015

10.1016/J.YGYNO.2008.12.015

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference